Am J Transplant, Volume 18, Suppl 3 Archives - Page 15 of 211 - ATC Abstracts

2018 American Transplant Congress
Defining Response to Standard of Care Treatment in Kidney Recipients with Antibody-Mediated Rejection: Role of C1q-Binding Donor-Specific Anti-HLA Antibodies
Y. Bouatou, D. Viglietti, O. Aubert, A. Loupy, C. Lefaucheur.
Paris Translational Research Center for Organ Transplantation, Paris, France.
A major hurdle to improving clinical care in kidney transplantation is the lack of biomarkers of the response to antibody-mediated rejection (ABMR) treatment. We investigated…
2018 American Transplant Congress
Comparison of Microvascular Inflammation in Renal Allograft Tissue between ABO Incompatible and ABO Compatible Kidney Transplantation
E. Ko,^1,2 B. Choi,^1,2 C. Park,^1,2 Y. Kim,^1,2 C. Yang,^1,2 B. Chung.^1,2
¹Transplant Research Center, College of Medicine, Seoul St.Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea; ²Division of Nephrology, Department of Internal Medicine, College of Medicine, Seoul St.Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.
Background: Microvascular inflammation (MVI) is considered as a pathological marker for antibody-mediated rejection (AMR) in the presence of donor-specific antibody (DSA). We aimed to investigate…
2018 American Transplant Congress
Interstitial Inflammation is Correlated with DQ Antibodies in Kidney Transplant Recipients
C. Harris, L. Anderson, R. Khaim, J. Choudhuri, R. Shapiro, S. Florman, F. Salem, M. Menon.
Icahn School of Medicine at Mount Sinai, New York.
Background: Studies have shown that borderline rejection (BR) and acute cellular rejection (ACR) often co-occur with antibody-mediated rejection (AMR). We examined the association between interstitial…
2018 American Transplant Congress
Decreased Clinical Significance of Isoagglutinin Titer with the Current Desensitization Protocol in ABO-Incompatible Kidney Transplantation
C. Baek, H. Kim, W. Yang, D. Han, S-.K. Park.
Department of Internal Medicine, Division of Nephrology, Asan Medical Center, Seoul, Republic of Korea; Department of Surgery, Asan Medical Center, Seoul, Republic of Korea.
ABO-incompatible (ABOi) kidney transplantation (KT) has become a routine procedure with graft survival rates comparable to those of ABO-compatible KT. However, the clinical significance of…
2018 American Transplant Congress
Evaluation of KPD: Does It Improve Overall Transplant Center Performance?
M. Rees,³ E. Michelin,¹ N. Koizumi,² J. Ortiz.³
¹West Virginia School of Osteopathic Medicine, Lewisburg, WV; ²George Mason University, Fairfax, VA; ³University of Toledo College of Medicine, Toledo, OH.
Introduction: The medical community is facing a constant shortage of kidneys for transplant patients. The most effective way to combat the deficit is to increase…
2018 American Transplant Congress
Relation between Seroprevalence of Cytomegalovirus and Graft Survival in Japanese Kidney Transplant Recipients: The Japan Academic Consortium of Kidney Transplantation Study
K. Miyake,^1,2 M. Okumi,¹ K. Unagami,³ Y. Kakuta,¹ H. Shirakawa,⁴ K. Omoto,⁵ H. Ishida,¹ K. Tanabe.¹
¹Urology, Tokyo Women's Medical University, Tokyo, Japan; ²Kidney Transplantation, Shonan Kamakura General Hospital, Kamakura, Japan; ³Nephrology, Tokyo Women's Medical University, Tokyo, Japan; ⁴Urology, Okubo Hospital, Tokyo, Japan; ⁵Urology, Toda Chuo General Hospital, Saitama, Japan.
BackgroundCytomegalovirus (CMV) infection is one of major causes of morbidity in kidney transplant recipients (KTRs). However, the current prevalence of CMV in KTRs and the…
2018 American Transplant Congress
Clinical Validation of a Novel ELISpot-Based In Vitro Diagnostic Assay to Monitor CMV-Specific Cell-Mediated Immunity in Kidney Transplant Recipients
B. Banas,¹ D. Steubl,² L. Renders,² D. Chittka,¹ M. Banas,¹ T. Wekerle,³ M. Koch,⁴ O. Witzke,⁵ A. Muehlfeld,⁶ C. Sommerer,⁷ A. Habicht,⁸ C. Hugo,⁹ T. Huenig,¹⁰ M. Lindemann,⁵ T. Schmidt,¹¹ A. Rascle,¹¹ S. Barabas,¹¹ L. Deml,¹¹ R. Wagner,^1,11 B. Kraemer,¹² B. Krueger.¹²
¹University Clinic, Regensburg, Germany; ²Clinic rechts der Isar TUM, Munich, Germany; ³Medical University, Vienna, Austria; ⁴University Clinic, Hamburg-Eppendorf, Germany; ⁵University Hospital, Essen, Germany; ⁶Uniklinik RWTH, Aachen, Germany; ⁷University Hospital, Heidelberg, Germany; ⁸LMU Medical Center, Munich, Germany; ⁹University Hospital, Dresden, Germany; ¹⁰University Hospital, Wuerzburg, Germany; ¹¹Lophius Biosciences, Regensburg, Germany; ¹²UMM Uni. Heidelberg, Mannheim, Germany.
Impaired cytomegalovirus (CMV)-specific cell-mediated immunity (CMV-CMI) is a major cause ofCMV reactivation and associated complications in solid-organ transplantation. Reliably assessing CMV-CMI is desirable to individually…
2018 American Transplant Congress
Evaluation of Salt Intake by 24-h Urinary Sodium Excretion in Kidney Transplant Patients
T. Abe,¹ M. Kawamura,¹ S. Nakazawa,¹ T. Kato,¹ R. Imamura,¹ N. Ichimaru,² S. Takahara,² N. Nonomura.¹
¹Departments of Urology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan; ²Departments of Advanced Technology for Transplantation, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Background: Dietary recommendations for chronic kidney disease advise 3 to 6 g/day of dietary salt intake. We evaluated current adherence to dietary recommendations for CKD…
2018 American Transplant Congress
Malignancy Complications after Kidney Transplantation, the Role of Immunosuppression
M. Molina,¹ J. Cabrera,² E. Gonzalez,¹ A. Hernández,¹ N. Polanco,¹ A. Andres.¹
¹Nephrology Department, Hospital Universitario 12 de Octubre, Madrid, Spain; ²Nephrology Department, Hospital Evangelico, Montevideo, Uruguay.
Introduction: Immunosuppression therapy is essential to avoid rejection after kidney transplantation. The chronic use of this drugs increases the risk of malignancy compared to general…
2018 American Transplant Congress
The Initial Hepatic Artery Reperfusion versus Initial Portal Reperfusion in Liver Transplantation: Where Do We Stand?
R. Shahbazov,¹ F. Azari,³ J. Alejo,² M. Talanian,² M. Fox,² K. Kennedy,² S. Kessel,² A. Nickkholgh,¹ D. Maluf,¹ S. Pelletier.¹
¹Surgery, University of Virginia Health System, Charlottesville, VA; ²School of Medicine, University of Virginia Health System, Charlottesville, VA; ³Surgery, University of Pennsylvania Medical Center, Philadelphia, PA.
Introduction: While initial portal vein reperfusion (PVRP) of a liver allograft is nearly standardized, limited data suggests initial hepatic arterial reperfusion (HARP) may improve hemodynamics…